1. Effects of omeprazole and ritonavir on absorption and elimination of the hepatitis C virus NS5A inhibitor GSK2336805 in healthy adults. Issue 5 (18th February 2014) Authors: Adkison, Kimberly K.; Jones, Lori S.; Lou, Yu; Gan, Jianjun; Wilfret, David A. Journal: Clinical pharmacology in drug development Issue: Volume 3:Issue 5(2014:Sep./Oct.) Page Start: 338 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Pharmacokinetics of hepatitis C virus NS5A inhibitor JNJ‐56914845 (GSK2336805) in subjects with hepatic impairment. (25th May 2015) Authors: Adkison, Kimberly K.; Gan, Jianjun; Elko‐Simms, Lucinda; Gardner, Stephen; Dumont, Etienne; Jones, Lori S.; Saunders, Joanne; Marbury, Thomas; Smith, William; Berg, Jolene; Galloway, Christopher; Stump, Patrick J. Journal: Journal of clinical pharmacology Issue: Volume 55:Number 9(2015:Sep.) Page Start: 1042 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Safety, tolerability, and pharmacokinetics of oral and intravenous administration of GSK1322322, a peptide deformylase inhibitor. (13th August 2013) Authors: Naderer, Odin J.; Jones, Lori S.; Zhu, John; Kurtinecz, Milena; Dumont, Etienne Journal: Journal of clinical pharmacology Issue: Volume 53:Number 11(2013:Nov.) Page Start: 1168 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. The effect of food and formulation on the pharmacokinetics, safety, and tolerability of GSK1322322 in healthy volunteers. Issue 1 (27th October 2014) Authors: Naderer, Odin; Jones, Lori S.; Zhu, John; Coffin, Mark D.; Kurtinecz, Milena; Dumont, Etienne Journal: Clinical pharmacology in drug development Issue: Volume 4:Issue 1(2015:Jan./Feb.) Page Start: 49 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗